Navigation Links
Report Highlights Successful Strategies for Bringing FDC Products to Market
Date:1/5/2011

CHAPEL HILL, N.C., Jan. 5, 2011 /PRNewswire/ -- The pharmaceutical industry's steep patent cliff and relatively lackluster pipeline is pushing strategy and development executives to uncover opportunities for sustainable growth in 2011. One opportunity lies in combination therapies with branded products to extend patent life. For pharma companies, fixed dose combination (FDC) products can extend a therapeutic advantage and become part of lifecycle management. For the patient, FDC products can address unmet medical needs and reduce pill burdens.

While FDC products can have clinical and commercial advantages, they also can be challenging to bring to market. A new Best Practices, LLC report found it takes between five and eight years and an average of $80 million to bring a FDC product to market. One of the keys to successfully commercializing a FDC therapy is to create a differentiated product with a therapeutic benefit, according to the research project.

Indeed, critical product-shaping strategies such as positioning and value were tactics that veteran FDC leaders identified as most valuable for a successful launch of a FDC product, according to "Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market." As one R&D veteran noted in the report, "Bring some value to the payers. If a payer looks at it and there's not really any kind of clinical differentiation, whether it's better efficacy, speed of onset, better response, or better remission, the payers tell us very, very clearly that they're not interested."

Some of the issues addressed in this research include:

  • Chief reason for pursuing FDC development
  • Measures used to evaluate success
  • Years from decision to develop through launch
  • Cost of FDC product development Approximate
  • Difficulty areas for bringing FDC product to market
  • Reasons for partnering with another company to develop FDC product
  • Time lapsed from initial contact to signed contractual agreement with partner
  • U.S. filing routes used
  • EU filing routes used
  • Months from filing to approval
  • Pre-launch marketing challenges
  • Strategies, tactics, practices to help accelerate or impede launch progress
  • Lessons learned from executives
  • Metrics for effectively communicating business value

The full 55-page report contains more than 150 benchmark metrics, providing executives with the tools, tactics and techniques to help organizations successfully develop and commercialize fixed dose combination products. Review a complimentary summary of the study at http://www3.best-in-class.com/rr1037.htm. The summary includes selected best practices drawn from extensive primary research with 51 representatives from 34 leading companies, including eight of the Top 20 pharma companies. 

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.  For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michigan Pre-Seed Capital Fund Reports Investments Totaling $2.5 Million in 2010
2. Elektas MOSAIQ Oncology Information System Named Category Leader in 2010 Top 20 Best in KLAS Awards Report
3. Reportlinker Adds Cosmetic Surgery Products
4. Complaints and Concerns about Medicare Competitive Bidding for Home Medical Equipment Can Be Reported Via a Toll-Free Number and Website
5. Reportlinker Adds Regenerative Medicine Markets
6. Reportlinker Adds Womens Health Diagnostic Testing
7. Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry
8. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
9. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
10. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
11. Reportlinker Adds Mammography World Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Summary GBI ... a Key Component of Multichannel Marketing" provides a ... in the digital age. While the pharmaceutical ... advancements, it has been much slower to adopt ... traditional channels and methods. However, the decreasing effectiveness ...
(Date:3/28/2017)... 2017  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... fourth quarter and year ended December 31, 2016. ... progress for Orexigen, beginning with the re-acquisition of the ... March, the team at Orexigen demonstrated remarkable focus, executing ... and strengthened our Company while rewarding us full control ...
(Date:3/28/2017)... and TORONTO , March 28, 2017 ... leading full service medical device development firm, announced today ... Toronto -based medical device industrial design ... serve medtech companies throughout North America ... experienced medical device talent spanning the design, engineering, regulatory, ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as it ... either don’t have access to a health care facility or a pharmacy within 60 minutes ... the United States or for many who are faced with health or personal issues that ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has ... to protect parental rights and civil liberties, and to restore transparency within government ... demonstration coincides with a press conference taking place Friday morning calling on President ...
(Date:3/28/2017)... ... , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts ... Secret. Dr. Wentz talked about journey and research recently on a blog and discussed ... the only solution to deal with thyroid disease. , Dr. Wentz completed her ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., a leading ... it has joined the National Association for Home Care and Hospice (NAHC), the ... and dying Americans of all ages and the caregiver who provide them with ...
Breaking Medicine News(10 mins):